Tocilizumab, a humanized anti-IL-6 receptor antibody is now approved for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis [100], but it may not exert an effect in reducing or ameliorating high IL-6 in the CNS in context of neurodegenerative diseases due to poor penetration of antibodies into the CNS. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.